Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001610717-26-000350
Filing Date
2026-08-05
Accepted
2026-08-05 19:32:10
Documents
2
Period of Report
2026-08-03

Document Format Files

Seq Description Document Type Size
1 FORM 3 form3.html 3  
1 FORM 3 form3.xml 3 1784
2 POWER OF ATTORNEY acarvajalpoa.htm EX-24.1 7391
  Complete submission text file 0001610717-26-000350.txt   10670
Mailing Address 151 OYSTER POINT BLVD. SUITE 400 SOUTH SAN FRANCISCO CA 94080
Business Address 151 OYSTER POINT BLVD. SUITE 400 SOUTH SAN FRANCISCO CA 94080 650.515.3185
CytomX Therapeutics, Inc. (Issuer) CIK: 0001501989 (see all company filings)

EIN.: 273521219 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address MERSANA THERAPEUTICS, INC 840 MEMORIAL DRIVE, 5TH FLOOR CAMBRIDGE MA 02139
Business Address
Carvajal Alejandra (Reporting) CIK: 0001645755 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-37587 | Film No.: 261245427